1

Sde Proteins Coordinate Ubiquitin Utilization and Phosphoribosylation to Establish and Maintain the *Legionella* Replication Vacuole

Running Title: Sde-mediated deubiquitination and ubiquitin phosphoribosylation.

Key terms: *Legionella*, macrophages, autophagy, ubiquitination, deubiquitination, intracellular replication

Kristin M. Kotewicz[1,#], Mengyun Zhang[1,&,#], Seongok Kim[1,@,#], Meghan S. Martin[2], Atish Roy Chowdhury[1], Albert Tai[3], Rebecca A. Scheck[2], and Ralph R. Isberg[1,*]

[1] Department of Molecular Biology and Microbiology, Tufts University School of Medicine, 150 Harrison Ave., Boston, MA 02111, USA
[2] Department of Chemistry, Tufts University, 62 Talbot Ave, Medford, MA, 02155, USA
[3] Department of Immunology, Tufts University School of Medicine, 150 Harrison Ave., Boston, MA 02111, USA

[#] These authors contributed equally to this work
[&] Current address: Global Health Drug Discovery Institute, Haidian, Beijing, China
[@] Current address: Department of Food Science & Biotechnology, and Carbohydrate Bioproduct Research Center, College of Life Science, Sejong University, Seoul, South Korea
*Corresponding Author: ralph.isberg@tufts.edu

Abstract

The *Legionella pneumophila* Sde family of translocated proteins promotes host tubular

endoplasmic reticulum (ER) rearrangements that are tightly linked to phosphoribosyl-ubiquitin

(pR-Ub) modification of Reticulon 4 (Rtn4). Sde proteins have two additional activities of

unclear relevance to the infection process: K63 linkage-specific deubiquitination and

phosphoribosyl modification of polyubiquitin (pR-Ub). We show here that the deubiquitination

activity (DUB) stimulates ER rearrangements while pR-Ub protects the replication vacuole from

cytosolic surveillance by autophagy. Loss of DUB activity is tightly linked to lowered pR-Ub

modification of Rtn4, consistent with the DUB activity fueling the production of pR-Ub-Rtn4. In

parallel, phosphoribosyl modification of polyUb, in a region of the protein known as the

isoleucine patch, prevents binding by the autophagy adapter p62. An inability of Sde mutants to

modify polyUb results in immediate p62 association, a critical precursor to autophagic attack.

The ability of Sde WT to block p62 association decays quickly after bacterial infection, as

predicted by the presence of previously characterized *L. pneumophila* effectors that inactivate

Sde and remove polyUb. In sum, these results show that the accessory Sde activities act to

stimulate ER rearrangements and protect from host innate immune sensing in a temporal fashion.

Introduction

Legionella pneumophila is a facultative intracellular bacterium that is the causative agent of Legionnaire's disease, a pneumonia of high lethality that primarily occurs in the immunocompromised and individuals with depressed lung function[1, 2]. Disease is usually associated with aspiration of droplets from contaminated water sources harboring amoebae that act as the environmental intracellular reservoir to support growth of the bacterium[3]. Once deposited within the lungs, productive infection involves growth of *L. pneumophila* within alveolar macrophages followed by attempted neutrophil clearing, which accumulates during productive pneumonic disease[4]. The ability of the bacterium to grow within macrophages is tightly linked to an environmental lifestyle that involves growth within amoebae, as establishing a niche within amoebal species provides the selective pressure for acquisition of genes that promote intracellular growth[5, 6]. Therefore, human disease promoted by the bacterium is a consequence of targeting host cell functions that are largely conserved from amoebae to man.

Intracellular growth of *L. pneumophila* requires construction of the *Legionella-*containing vacuole (LCV), which is derived from host membranes and is tightly associated with host endoplasmic reticulum and the early secretory apparatus[7, 8]. The LCV avoids interaction with the endocytic pathway including the highly antimicrobial lysosome[9]. Biogenesis of the bacterial compartment requires the function of the Icm/Dot type IV secretion system that acts as a syringe to deposit translocated bacterial effector proteins into the surrounding membrane as well as into the cytosol[10, 11]. Every *Legionella* species member encodes at least 300 of these effectors, which are remarkably poorly conserved, with only seven proteins found in all species[12, 13]. The biochemical activities of a large number of these proteins have been identified, many of which perform posttranslational modifications (PTMs) on host proteins, conferring activation, inhibition, altered regulation or acquisition of new functions on the target proteins[14]. The most notable consequences of these activities are to maintain the integrity of the LCV[15], promote association with proteins involved in endoplasmic reticulum dynamics[16], inactivate host

components that drive association with the endocytic compartment [17], and inhibit protein

synthesis[18].

One set of Icm/Dot system translocated proteins that drives a unique morphological

transformation of the LCV is the Sde family (SidE, SdeA, SdeB and SdeC)[19, 20, 21, 22]. The

importance of this family is emphasized by the discovery that at least five other *L. pneumophila*

translocated substrates regulate the dynamics of this family[23, 24, 25, 26, 27, 28]. As is true of many

Icm/Dot substrates, each member is a composite of three enzymatic activities located on separate

domains (Fig. 1A)[29, 30, 31]. A mono-ADPribosyltransferase (mART) domain drives NAD-

dependent ADPribosylation of diverse ubiquitin species at Arginine 42 (ADPr-Ub)[20, 22]. In turn, a

phosphodiesterase-like domain (PDE) can use ADPr-Ub to either promote phosphoribosyl

linkage of Ub (pR-Ub) to substrates, or hydrolysis to generate free phosphoribosylated-Ub[21, 22].

The DUB domain is an accessory activity that preferentially deubiquitinates Lys63-linked

polyubiquitin chains[32]. A number of potential mammalian substrates have been shown to be pR-

Ub modified by Sde members on serine residues that are located in relatively unstructured

regions of proteins[29, 30]. Work with model substrates indicates that tyrosine residues may also be

targeted[33]. Although the number of Sde substrates is likely to be quite large given the structural

preference for pR-Ub modification, modifications of endoplasmic reticulum protein Rtn4[22] and

Golgi-associated GRASP family members appear most closely tied to events involved in LCV

biogenesis[27, 34]. In the absence of DUB activity, there is accumulation of polyUb about the

replication vacuole, with unknown consequences on replication vacuole formation or

intracellular growth[32].

Immediately after *L. pneumophila* is internalized by macrophages, pR-Ub modification of

Rtn4 drives replication vacuole association with endoplasmic reticulum tubules. This modification

results in highly detergent-resistant structures that appear to wall off the LCV from the host cell

cytosol[22], in a process that contributes to the protection of the LCV from attack by early endosomal

components that degrade the vacuole[35]. Simultaneously, there is accumulation of

polyubiquitinated targets in the vicinity of the LCV[36, 37, 38, 39, 40], which appear to be targets of the

Sde DUB domain[32, 41]. Phosphoribosyl modification of polyUb by Sde proteins stabilizes these

structures, by blocking wholesale reversal of polyubiquitination by both bacterial and host

DUBs[42]. Accumulation of polyUb potentially provides a target for the host cell autophagy pathway

that could drive degradation of the LCV[43, 44, 45]. *L. pneumophila* appears to have several systems

for blocking autophagic recognition of the LCV, including degradation of central components of

the autophagy machinery by the Icm/Dot effector RavZ[46], degradation of syntaxin 17 by effector

Lpg1137[47], reduction of sphingosine levels by LpSpl[48] as well as the described

phosphoribosylation[49].

In this study, we report the role of the DUB and phosphoribosylation accessory activities

of Sde family members. We show that the DUB domain surprisingly increases the efficiency of

Rtn4 mobilization in the vicinity of the LCV, while ADPribosylation or phosphoribosylation of

Ub interferes with autophagy by blocking binding of polyUb to an autophagy adaptor, primarily

by phosphoribosylation of target Ub chains in the LCV vicinity. Similar results have been

obtained in the simultaneously submitted manuscript by Wan, *et al.*[50]

Results

The Sde DUB activity is required for efficient Rtn4 rearrangements in response to *L.*

***pneumophila*.**

To determine if there is a link between the Sde family K63 deubiquitinase (DUB) domain

(Fig. 1A) and biogenesis of the *Legionella*-containing vacuole (LCV), the kinetics of

polyubiquitin (polyUb) association and Rtn4 rearrangements in the vicinity of the LCVs were

analyzed. A previous study had shown that the absence of the DUB domain resulted in a 2-fold

increase in polyUb in the vicinity of the LCV[32]. Bone marrow-derived macrophages (BMDMs)

were challenged with *L. pneumophila* derivatives lacking the complete complement of *sde*

family members (*sidE*, *sdeABC*), which removes all proteins known to control Rtn4 dynamics[19].

After 5 min centrifugation onto BMDMs, followed by fixation and probing with a polyUb-

specific antibody (FK1), there was no evidence of polyUb in the vicinity of the LCV of a WT

strain containing empty vector (Fig. 1B; 0 minutes post infection (MPI)). In contrast, challenge

with *L. pneumophila* missing all *sde* family members (Δ*sde*) resulted in approximately 24% of

the LCVs displaying polyUb association. By 10 MPI, ~25% of the vacuoles containing WT

strain positively stained with polyUb, approximately 2-3X lower than the Δ*sde* strain at this

timepoint, consistent with previous observations (Fig. 1B; [32]). At 0 MPI, Δ*sde* mutants were

efficiently complemented by all three members of the Sde family known to have biological

activity (SdeA, SdeB and SdeC; Fig. 1B). Surprisingly, for all complemented strains, polyUb

quickly rose to the levels seen in the absence of Sde family function (Fig. 1B; 30 MPI). The

presence or absence of empty vector had no effect on the behavior of the WT strain

(Supplemental Fig. S1). We conclude that inhibition of the polyUb association with the LCV

occurs transiently. The fact that the inhibition is transient is consistent with the LCV-associated

polyUb chains becoming resistant to the action of the DUB domain by 30 minutes post-infection

(MPI).

The biological significance of having a K63 deubiquitinase activity is unclear, especially

because the ART activity of Sde proteins directly blocks deubiquitination, arguing that the DUB

may play some role other than reducing LCV polyubiquitination [22, 42]. Alternatively, the DUB

activity could modulate the dynamics of Rtn4 rearrangements associated with the LCV[22]. To test

this model, BMDMs were challenged with *L. pneumophila* derivatives having defective DUB

activity followed by probing for Rtn4 detergent-resistant structures in the LCV vicinity (Fig. 1C) [22].

Surprisingly, the inactive DUB mutant (C118S) resulted in lowered Rtn4 colocalization with the

LCV. In a strain expressing SdeC as the sole demonstrated driver of Rtn4 rearrangement, the

C118S mutation reduced detergent-resistant Rtn4 association with the LCV by over 60% (Figs.

1C).

Consistent with data in Fig. 1C, Rtn4 association with the LCV was robust in strains

expressing SdeB or SdeC as the sole plasmid-expressed isoforms (Figs. 1G,H) and

indistinguishable from the WT strain (Fig. 1D). In contrast, loss of *sdeC-A* prevented Rtn4

association with the LCV, as did elimination of the T4SS (Figs. 1E, F). The presence of the

C118S mutation resulted in two populations, with a mixture of detectable Rtn4-colocalization

with LCVs or RTN4 staining below the level of detection (Fig. 1I). Similar results were seen

with the DUB D80A catalytic mutant, whereas a control Cys mutant C293A showed high levels

of colocalization (Supplemental Fig. S2). These results are consistent with the DUB domain

playing a role in LCV biogenesis at the level of controlling Rtn4 dynamics.

To test if the Sde DUB activity plays a direct role in promoting Rtn4 rearrangements, we

determined if the catalytic domain contributed to the rate of Sde-dependent phosphoribosyl-

ubiquitin (pR-Ub) modification of Rtn4. In a purified system, pR-Ub modification of Rtn4 is

rapid and robust with the presence of excess mono-Ub[22, 33]. In contrast, infection provides

multiple potential sources of Ub, including K63-linked polyUb, which the DUB activity could

target to provide substrate for pR-Ub modification. To test this hypothesis, HEK293T cells

transfected with HA-Ub were challenged by *L. pneumophila* harboring either WT or DUB-

defective (C118S) derivatives as the only active Sde family members. At 10 or 180 MPI, cells

were extracted and subjected to immunoprecipitation with anti-Rtn4, followed by

immunoprobing with anti-HA to reveal Rtn4 ubiquitination (Fig. 1J). Detectable mono- and di-

modification of the Rtn4B and Rtn4B2 isoforms were observed as early as 10 MPI with

continued increase at 180 MPI in response to the WT strain (Fig. 1J, WT). In contrast, challenge

with Δ*sde* mutants showed HA-Ub modification that was indistinguishable from mock-infected

controls (Fig. 1K; vector vs. Mock). Challenge with Δ*sde* mutants harboring single SdeA or

SdeB isoforms each showed rescue of the HA-Ub modification defect, and their rescue was

largely eliminated by the presence of the C118S catalytic mutation (Fig. 1K; compare p*sdeA* and

psdeB to the respective C118S derivatives). Therefore, the absence of Sde DUB activity results

in a strong reduction in both detergent-resistant Rtn4 and Ub modification of Rtn4, strongly

arguing that Sde-mediated deubiquitination of K63-linked polyUb plays a role in LCV dynamics,

possibly providing a pool of mono-Ub substrate for the ART domain.

ADPribosylation of ubiquitin by Sde results in hyper-ubiquitination of the LCV.

The presence of robust polyUb association with the LCV in the absence of the DUB

domain indicates that pR-modification probably stabilizes polyUb (Fig. 1). This is inconsistent

with the previous model that pR modification of Ub plays a role in blocking polyubiquitination

during LCV formation[21]. Rather, it seems likely that pR-modification and ADP-ribosylation act

to block both bacterial DUBs as well as a variety of host-encoded K63- and K48-specific DUBs

(Fig. 2A)[42]. This was verified by incubating poly Ub_{3-7} (Ub chain lengths 3-7) with WT SdeC

and active site mutants prior to incubation with either a low linkage-specificity DUB (USP2) or

K63- and K48-specific DUBs of eukaryotic origin. Both WT enzyme (promoting pR

modification) and the PDE(-) mutant (promoting ADPr modification) uniformly blocked DUB

activity on either K48- or K63-linked $Ub_{3-7,}$ similar to what was observed previously (Fig. 2A)[42].

As observed previously, the absence of the ART domain resulted in quantitative hydrolysis of

the K63 polyUB chain by the SdeC DUB domain, leaving monomeric Ub that was poorly

resolved after probing with a poly-UB specific antibody (Fig. 2A, ART⁻) [22]. As predicted, this

hydrolysis in the absence of ART activity was less efficient with the K48-linked substrate[22, 42].

The fact that ADPr modification blocked DUB activity allowed us to interrogate the

consequences of Ub modification without confounding Rtn4 rearrangements promoted by the

PDE domain.

207   To analyze *L. pneumophila* derivatives altered in Sde family function, BMDM

monolayers were challenged for 20 min, and changes in polyUb in the LCV vicinity were

analyzed by probing fixed samples with a polyUb-specific antibody (Fig. 2B). Neither $sdeC_{C118S}$

(DUB⁻) nor $sdeC_{E859A}$ (ART⁻) mutants showed significant increases in polyUb fluorescence

intensity/vacuole if the analysis were restricted to LCVs having associated polyUb (Fig. 2B). In

contrast, challenge with the *L. pneumophila* PDE⁻ mutant resulted in dense accumulation of

LCV-associated polyubiquitination in spite of the fact that Rtn4 rearrangements were blocked

(Fig. 2B). This dense association was maintained over time (Fig. 2C). Most notable was the

presence of unusual polyUb-modified structures after challenge with the PDE⁻ mutant. While the

Δ*sde* and ART⁻ mutants showed polyUb staining about individual LCVs (Figs. 2E,G), the PDE⁻

mutant showed polyUb structures that wrapped around the LCV and extended into serpentine

structures across the interior of the BMDM (Fig. 2H). We occasionally observed dense structures

in response to challenge with the DUB⁻ mutant as well (Fig. 2F), but the frequency was little

changed from WT (Figs. 2B,C). We conclude that Sde-mediated modification of polyUb chains

stabilizes LCV-associated Ub from the attack by both bacterial- and host derived DUBs. The

observed deregulation of associated polyubiquitination in the absence of PDE activity indicates

that direct modification of Ub is sufficient to stabilize polyUb. Furthermore, there is no evidence

that pR- or ADPr-Ub modification plays a role in blocking polyubiquitination.

226   **Sde family members exclusively modify Arg42 residues throughout poly-Ub chains.**

The data showing that either pR- or ADPr-Ub modification stabilizes poly-Ub chains is

consistent with Sde family members blocking recognition of poly-Ub by proteins that bind

polyubiquitin chains. Previous work has shown that the Arg42 residue on mono-Ub is modified

by either SdeA and SdeC[20, 21, 22], indicating that phosphoribosylation of this residue is likely to

be the critical event that blocks recognition by other proteins. However, no evidence has been

provided that poly-Ub is quantitatively modified on the Arg42 residue, leaving the possibility

that the blockade witnessed in our experiments may be due to alteration at other sites internal to

poly-Ub. To demonstrate that internal Ub monomers within poly-Ub chains are quantitatively

modified at Arg42, K63-linked Ub_4 tetramers were incubated with SdeC-WT protein in the

presence of NAD and analyzed by liquid chromatography-mass spectrometry (LC-MS; Fig. 3A;

Methods)[22]. In the absence of SdeC, unmodified Ub_4 protein was observed with a deconvoluted

molecular mass of 34,206.75 AMU. Incubation of SdeC with Ub_4 at a ratio of 1:750 (SdeC: Ub_4)

for 1 hr resulted in 96.5% of the Ub_4 population increasing in mass by 848.21 AMU,

corresponding to four modifications with mass=212.05 AMU, as predicted by four pR additions.

These modified and unmodified Ub_4 preparations were digested with trypsin, and subjected to

LC-MS/MS to determine if the pR modifications were found exclusively on Arg42 (Fig. 3B), as

they were for monomeric Ub[22]. An ion unique to the SdeC-treated preparation was identified at

m/z=627.6392, z=3, as predicted for the 10-residue tryptic peptide containing the pR-modified

Arg42 residue and as shown by extracted ion chromatogram (EIC). In contrast, no such peptide

was present in the untreated samples (Fig. 3B). Furthermore, peptides containing the other Arg

residues in Ub, Arg54 and Arg72, were indistinguishable in the SdeC-treated and untreated

control, arguing against their modification in poly-Ub. A two amino acid tryptic fragment

containing Arg74 was too small to be resolved in either sample.

The 10-residue fragment from the Sde-treated sample was subjected to b- and y-ion

analysis after LC-MS/MS to demonstrate that Arg42 was the modified residue (Fig. 3C).

Modification of R42 by pR predicts that y ions beginning with y_7 and successively larger peptide

ions should have an increase in mass of 212.05 AMU, while y_6 and shorter peptides should show

no such increase. These ions were identified with high resolution, as were many other y ions

leading up to, and beyond R42, yielding m/z ratios expected of pR modification at this site and

not at other residues. Analysis of b ion data supported the y ion identifications. Additionally, no

ions corresponding to the mass of unmodified R42 could be identified in SdeC-treated samples.

Therefore, modification of poly-Ub occurs with the identical specificity of mono-Ub and

similarly results in quantitative addition of pR to R42 using limiting amounts of enzyme relative

to substrate.

Sde-mediated modification of polyUb blocks autophagy adaptor SQSTM1/p62 binding via

UBA domain.

The Ub Arg42 residue is a key target for modulating ubiquitin dynamics. Autophagy

adaptors such as p62 link ubiquitinated compartments to LC3-decorated phagophores via

ubiquitin associated (UBA) domains that recognize a hydrophobic patch on the Ub surface[51, 52].

Integral to this patch are the residues I44, V70 and L71, directly proximal to R42, the target

residue of ADPr modification by Sde (Fig. 4A, blue arrows). Structural analysis has shown that

R42 can directly participate in the UBA interface (Fig. 4B) and is likely involved in p62

recognition based on NMR analysis[53, 54]. We therefore tested if modification of the Ub at Arg42

residue blocks recognition by the p62 autophagy adaptor.

His-p62-Ni-NTA resin was challenged with K48- or K63-linked Ub_{3-7} mixed polymers

that had been pretreated with SdeC WT or its catalytic mutant derivatives (Methods). The

unbound fraction was collected (FT; flow through), and the p62-associated Ub_{3-7} (Eluate) was

detected after co-elution with imidazole, followed by SDS-PAGE fractionation and

immunoprobing with anti-Ub (Fig. 4C). In the absence of SdeC, both K48- and K63-linked Ub_{3-7}

were efficiently co-eluted with p62 (Fig. 4D; no SdeC preincubation). In contrast, pretreatment

with the SdeC WT, DUB⁻ (C118S) or PDE⁻ (H416A) derivatives all reduced K63- or K48-linked

Ub_{3-7} binding to p62 (Fig. 4D; E lanes). This indicates that either pR- or ADPr-modification of

polyUb blocks p62 recognition. In the case of the K48 derivative, the loss of the ART domain

restored Ub_{3-7}-p62 coelution, however it caused depolymerization of K48-linked Ub_{3-7} into

monomeric Ub, making the effects of this mutant difficult to evaluate in this assay (Fig. 4D;

E859A).

To determine the effects of Ub Arg42 modification in a more quantitative assay, binding

affinities to Ub_4 were determined using surface plasmon resonance (SPR) in the presence of a

DUB inhibitor (Ub-propargylamide, Ub-PA) to prevent degradation of the Ub_4 polymer

(Supplemental Fig. S3). K63-linked Ub_4 was modified by SdeC WT or its catalytic mutant

derivatives in the presence of Ub-PA (Methods), the modified K63-linked Ub_4 was introduced

onto flow chips with immobilized p62, and binding was measured by SPR over time (Fig. 4E). In

the absence of SdeC, Ub_4 bound His-p62 with apparent $K_D = 1.2 \times 10^{-7}$ to 6.2×10^{-8} M,

indicating that binding affinity was at least as efficient as previous SPR studies using diUb as a

substrate ($K_D = 9.3 \times 10^{-8}$ M [55]) (Fig. 4F). Binding of p62 to mono-Ub was very poor, consistent

with DUB activity interfering with recognition of p62, with binding constants that could not be

reliably determined by SPR (Fig. 4G, Fig. S3). Ub_4 pretreated with SdeC, either in the presence of

Ub-PA or having the C118S DUB mutation, resulted in blockade of p62 binding, consistent with

phosphoribosylation blocking recognition of Ub by UBA domains (Figs. 4H,I). ADPr

modification of Ub at Arg42 was sufficient to block binding, as the $SdeC_{H416A}$ PDE⁻ mutant

blocked binding as efficiently as WT (Fig. 4J). In all cases in which modification blocked p62

recognition, the binding constants could not be reliably determined by SPR. Elimination of the

ART activity restored Ub_4 binding to p62, with a similar binding affinity to untreated, consistent

with PA blocking the DUB activity (Fig. 4K; $K_D = 1.6 \times 10^{-7}$ M). These results strongly argue

that modification of the Ub at Arg42 residue by SdeC disrupts recognition by p62.

Sde-mediated modification of polyUb chains prevents association of p62 with the LCV.

To determine if Sde proteins enzymatically camouflage the replication vacuole from

recognition by p62, BMDMs were challenged with *L. pneumophila sde* variants and probed for

p62 localization in the vicinity of the LCV. A variety of p62 morphological variants were

observed, including LCV-associated puncta and LCVs enveloped by p62 (Supplemental Fig. S4).

After bacterial contact (5 min centrifugation) and immediate fixation, LCVs harboring *L.*

pneumophila WT showed no envelopment of p62 (Fig. 5A). In contrast, a large fraction of the

vacuoles after challenge with the *L. pneumophila* Δ*sde* strain were enveloped by p62 (Fig. 5B).

As time progressed, a variety of morphologies became apparent, such as the alignment of puncta

proximal to the LCV. As puncta associated with the LCV were difficult to distinguish from those

in the general vicinity, we limited quantification to identifying vacuoles with enveloping p62

structures and determining total p62 intensity associated with individual vacuoles.

Immediately after bacterial contact with BMDMs, both the WT and the T4SS⁻ strains were

devoid of p62 staining (Fig. 5C). In contrast, approximately 30% of the *L. pneumophila* Δ*sde*

bacteria were found to be enveloped by p62 (Fig. 5C). Colocalization was largely lost when either

sdeA, sdeB, or sdeC expressed on plasmids was introduced into the Δ*sde* strain. Quantification of

p62 signal associated with the LCV showed that there were two populations of bacteria after

challenge with the Δ*sde* strain, with a population showing p62 recruitment levels that were similar

to WT and a second population with 8-10X higher fluorescence intensity (Fig. 5D). In contrast,

the WT and Δ*sde* strains harboring Sde isoforms *in trans* showed indistinguishable low levels of

p62 recruitment (Fig. 5D).

As the infection proceeded, colocalization of p62 with the Δ*sde* strain continued to

increase (Fig. 5E, >50% at 20 MPI) with the population of LCVs strongly skewing toward

hyperaccumulation of p62 (Fig. 5F). Concurrently, a second phenomenon became apparent in

strains harboring plasmids that produced excess Sde isoforms. There was clear complementation

of the Δ*sde* defect (Fig. 5E), but accumulation of p62 in the vicinity of the LCV at 20 MPI was

observed that distinguished these constructs from the WT strain (Fig. 5E). Accumulation could

also be observed when the fluorescence intensity of individual LCVs was determined, with a

population emerging with increased p62 density (Fig. 5F). This phenomenon appeared to be a

premature version of what occurs with the WT strain, as 20% of the LCVs harboring the WT

showed accumulation of p62 by 60 MPI, with evidence of an emerging population showing

increased p62 density in the LCV vicinity (Figs. 5G, H). There was robust accumulation of p62

about individual LCVs harboring WT strain at this timepoint that appeared indistinguishable

from individual LCVs harboring the Δ*sde* strain (Fig. 5I). Furthermore, at 180MPI, accumulation

of p62 around the LCV in the Δ*sde* strain was indistinguishable from p62 accumulation around

WT LCVs (Figs. 5J, K). When the percentage of LCVs associated with p62 was plotted as a

function of time post-infection (Fig. 5L), there was early accumulation of p62 that was blocked

by the Sde family (0-20 MPI). This was followed by decay of p62 accumulation after infection

of the Δ*sde* strain, while the WT showed increasing p62 between 20 and 60 MPI, resulting in a

convergence of the phenotypes (180 MPI). The loss of Sde protection of the LCV is consistent

with reversal of its activity by known metaeffectors SidJ and DupA/B [24, 25, 26, 56].

To determine the role of the individual Sde activities in preventing p62 accumulation,

point mutations in each of the three catalytic domains were analyzed at 0 MPI after macrophage

challenge, when the Sde family exerts its most striking effects. Mutations in *sdeB* were introduced

into the Δ*sde* strain, as this isoform showed the most effective complementation (Fig. 5C), and

these mutants were then used to challenge macrophages. Point mutations in the catalytic sites of

the DUB or PDE domains, as well as a double mutant missing the catalytic activity in both of

these domains, still retained the ability to block p62 colocalization after association (Figs. 6A-C).

In contrast, a mutation in the ART domain caused a large increase in p62 recruitment to LCVs,

indicating that ADP ribosylation of Ub Arg42 by the ART domain blocks p62 recognition of the

LCVs (Fig. 6A). The presence or absence of empty vector in the WT strain had little effect on this

result (Supplemental Fig. S5). It should be noted that there appeared to be some residual

interference of p62 in the single ART mutant, but this was eliminated by simultaneously

introducing a DUB mutation, indicating that the DUB domain may play a minor role in lowering

p62 recognition of the LCV (Fig. 6A). As seen with the Δ*sde* strain, the ART mutants resulted in

a clear subpopulation showing approximately 10-fold increase in p62 accumulations (Figs. 6B,C).

These results support the biochemical data that either ADPribosylation or phosphoribosylation of

Ub at Arg42 is sufficient to block p62 recognition. It also argues against models that propose pR-

linked Ub modification of a peripheral factor plays a role[57], as ADPribosylation of Ub was

sufficient to interfere with p62 recruitment.

Discussion.

The *L. pneumophila* Sde family drives phosphoribosyl-linked ubiquitination (pR-Ub) of targets, most spectacularly leading to largescale rearrangements of the tubular ER protein reticulon 4 (Rtn4)[22]. In addition, there are two accessory activities of Sde proteins that have unclear biological roles. The Sde deubiquitinase (DUB) domain preferentially deubiquitinates Lys63-linked polyubiquitin chains (Fig. 1)[32], while the other is the hydrolytic product of ADPribosylated ubiquitin (ADPr-Ub), resulting in phosphoribosylated ubiquitin (pR-Ub)[22, 58]. The phosphoribosylation occurs at the Ub Arg42 residue, strategically placed in a hydrophobic patch that provides a recognition surface for ubiquitin binding proteins that drive autophagy (Fig. 3C; Fig. 4A,B)[53, 59]. The presence of Sde family members is linked to a lowered association of Ub-recognizing autophagy adaptors to the LCVs[49], consistent with phosphoribosylation promoting maintenance of the LCV in the face of cytosolic antimicrobial attacks.

In this manuscript, we showed that inhibition of polyUb formation about the replication vacuole was transiently controlled by the Sde DUB domain and limited to the earliest times after infection (Fig. 1). This early degradation of polyUb by the DUB domain fueled phosphoribosyl-linked ubiquitination because pR-Ub modification of Rtn4 slowed greatly in the absence of DUB activity and was accompanied by a reduction in Rtn4 accumulation about the replication vacuole (Fig. 1D-M). Therefore, it appears that there is K63-polyubiquitination of the LCV about the nascent replication vacuoles[39, 60, 61, 62, 63, 64] that provides the substrate for the Sde DUB activity, generating monoubiquitin fuel for the Sde mART domain (Fig. 7B,C). This is then directly transferred by the PDE domain to generate pR-Ub modified Rtn4, allowing a direct pathway from vacuolar polyUb to endoplasmic reticulum (ER) rearrangements (Fig. 7D).

The association of polyUb with the replication vacuole should be a suicide signal for *L. pneumophila*, as ubiquitination marks intracellular compartments for degradation by the autophagy pathway[45, 65]. Autophagy results from binding of adaptor molecules (such as p62) to Ub-modfied compartments which, in turn, bridge to autophagophores decorated by LC3/Atg8[66]. It is well established that after *L. pneumophila* forms the LCV, autophagy is blocked via the action

of the Icm/Dot substrate RavZ, which irreversibly hydrolyzes and deconjugates LC3/Atg8 from

the nascent autophagophore, blocking binding to autophagy adaptors[46]. In the absence of RavZ,

the LCV is still resistant to autophagy, indicating that the vacuole is masked in a fashion that

prevents recognition by the LC3-decorated autophagophore[46, 49]. We show here that modifying

the Arg42 residue of polyUb with either mono-ADPribose or phosphoribose physically blocks

binding to the autophagy adaptor p62 (Fig. 4), and similar results have been obtained by Wan and

coworkers[50]. Surface plasmon resonance experiments showed no detectable p62 binding in

presence of high concentrations of polyUb modified by either WT (pR modification) or the

H416A derivative (ADPr modification; Fig. 4F-K). Consistent with the data using purified

proteins, both modifications blocked p62 association with the LCV (Fig. 6) and stabilized polyUb

about the replication vacuole (Fig. 2). In fact, the ADPr modification resulted in

hyperaccumulation of polyUb about the replication vacuole (Fig. 2B,C), consistent with enhanced

resistance to both DUBs and autophagy adaptor recognition.

That all the proposed functions of phosphoribosylation can be fulfilled without hydrolysis

of the ADPr modification questions the purpose of the pR modification. It seems likely that

allowing vacuole-associated polyUb to accumulate ADPr modifications would result in covalent

linkage of Sde targets directly to the replication vacuole, even if this is a low likelihood event [22,

27, 34]. In addition, the ART and PDE domains work independently and consecutively, allowing

ADPr modification to persist on polyubiquitin chains, raising the possibility that unwanted

proteins would be immobilized about the replication vacuole. This problem is particularly

exacerbated by the fact that Sde-promoted pR-Ub linkage preferentially occurs on unstructured

regions of proteins, which could drive promiscuous linkage of poorly folded proteins about the

vacuole. Therefore, hydrolysis of ADPr-Ub at Arg42 acts as a timing device, requiring target to

be immediately accessible to Sde and ADPr-Ub prior to decay to pR-Ub.

It has been previously reported that pR-Ub modification of USP14, a host cell

deubiquitinase, is a central strategy for preventing p62 association with the *Legionella* replication

vacuole[57]. The authors proposed that modification of USP14 disrupted its direct interaction with

p62, preventing association of the LCV with the autophagy adaptor[57]. The data we presented here

argue against USP14 modification being a major mechanism for autophagy avoidance, and that

modification of LCV-associated Ub is likely the primary strategy used by Sde proteins to protect

against autophagy. First, pR-modification of Ub blocked p62 association (Fig. 4), and, given the

expected stoichiometry of Ub relative to USP14, it is likely that this direct blockade is the primary

contributor to autophagy avoidance. Secondly, ADPr-modification of poly-Ub was sufficient to

avoid autophagy (Figs. 2B, 5A), arguing that pr-Ub modifications of any peripheral targets such

as USP14 are unlikely to contribute to autophagy avoidance. Finally, we showed that there was a

minor, but detectable, contribution of the DUB domain to autophagy avoidance (Fig. 5A),

consistent with host DUBs making similar enzymatic contributions, rather than playing a role in

direct binding to the p62 target.

Our data on the transient nature of p62 blockade illustrates an important biological

principal underlying Sde family function (Fig 4L). There is little, if any, association of p62 with

the *L. pneumophila* WT replication vacuole during the first 20 minutes of macrophage infection.

In contrast, challenge with the Δ*sde* strain results in p62 association with the LCV at early

timepoints (Figs. 4E,L). This huge difference largely disappears by 1 hour post infection, as there

appears to be increased accumulation of p62 about the WT LCV, with coordinate decreased p62

accumulation about the Δ*sde* LCV (Fig. 4L). By 3 hr post infection, the Δ*sde* mutant and WT look

indistinguishable, with each showing about 80% of the LCVs devoid of p62 localization.

Therefore, function of Sde decays rapidly during the first hour after infection, with a new activity

appearing in both strain backgrounds that interferes with p62 association.

The decay in protection from p62 association is predicted by the function of proteins that

modulate Sde family activity. Icm/Dot translocated proteins SidJ and SdjA glutamylate Sde

proteins, blocking their ability to ADPribosylate ubiquitin[23, 24, 25, 26]. As expression of the *sde*

genes appears to be downregulated after contact with mammalian cells[19, 67], this modification

effectively removes the pool of enzyme capable of ADPribosylating Ub. The fact that over time

there is some increase in the level of p62 association with the WT LCV indicates that there is

accumulation of polyubiquitin in the LCV vicinity during the first hour after infection that cannot

be modified by the inactivated Sde enzymes. In this regard, it should be noted that pR-Ub

modification of target proteins is also reversed by the linkage-specific deubiquitinases DupA and

DupB, consistent with a general decay in Sde function as well as loss of memory of its activity

during the first hour after infection[27, 28]. Therefore, Sde functions as critical cog in the

morphogenesis of the LCV during the earliest stages of replication vacuole establishment.

Efficient intracellular growth requires decay in Sde function, as SidJ mutants that result in

extended Sde family activity show slowed intracellular growth[68].

In summation, the Sde family is involved in critical early steps that are associated with

homeostatic regulation of replication vacuole morphogenesis. Accessory activities that modulate

polyubiquitin dynamics about the replication vacuole are tightly linked to phosphoribosyl-linked

ubiquitination of substrate (Fig. 7). We argue that the DUB domain provides fuel for pR-Ub

modification, while pR modification of polyubiquitination associated with the LCV prevents

attack by an important arm of host cell cytosolic defense. Finally, the transient nature of Sde

function during replication vacuole formation is an intrinsic feature of this system, as we witness

decay in the ability to block the autophagic response. The transient nature of providing fuel for

Sde function is also supported by this work, as phosphoribosyl modification of polyUb is

predicted to block DUB function (Fig. 2) and reduce the amount of fuel to support Sde-mediated

ubiquitination of substrates. The biological importance of limiting Sde function to the earliest

stages of replication compartment biogenesis requires further investigation.

Methods

Ethics statement.

All research complies with biosafety and animal welfare regulations as overseen by the

Tufts University Institutional Biosafety Committee and Institutional Animal Care and Usage

Committee.

Bacterial culture and media

L. pneumophila derivatives used in these studies were streptomycin-resistant restriction-

defective thymidine auxotrophs derived from a clinical isolate of *Legionella pneumophila*, strain

Philadelphia-1 (Lp01)[11, 69, 70]. *L. pneumophila* strains were propagated on charcoal–N-(2-

acetamido)-2-aminoethanesulfonic acid (ACES)–yeast extract plates, with or without thymidine

as needed (CYE/T) and in ACES-yeast extract broth (AYE/T)[7, 11, 71]. Plasmids were introduced

as described[22].

For the infection of mammalian cells, *L. pneumophila* strains were grown overnight to

post-exponential phase (OD_{600} 3.5-4.5) to a predominantly motile state[72]. *Legionella*

pneumophila derivatives are described in Supplemental Table S1, *Escherichia coli* derivatives

are described in Supplemental Table S2 and oligonucleotides used in this study are listed in

Supplemental Table S3.

Eukaryotic cell culture

Mice were housed at the Tufts University School of Medicine IACUC facility, with

housing and all manipulations detailed in approved protocol B2021-119. Bone marrow-derived

macrophages (BMDMs) were isolated from femurs and tibias of female 6-10week old A/J mice[7]

and frozen in fetal bovine serum (FBS) with 10% dimethyl sulfoxide (DMSO). Mouse strain

verifications provided by Jackson Laboratories (Bar Harbor, ME). Approximately 3 mice were

sufficient for all experiments performed. Cells were plated the day before infection in RPMI

1640 (Gibco) supplemented with 10% FBS and 2 mM glutamine at 37°C with 5% CO_2.

HEK293T cells, obtained from ATCC (not independently authenticated after being obtained),

were cultivated in Dulbecco modified Eagle medium (Gibco) supplemented with 10% heat-

inactivated (FBS, Invitrogen) (vol/vol), 100U/ml of penicillin-streptomycin (Gibco) at 37°C with

5% CO_2.

Polyubiquitin colocalization with LCV

BMDMs were plated on glass coverslips at 1-2 x 10^5/well in 24-well plates. Cells were

challenged at a multiplicity of infection (MOI) = 1, centrifuged at 200 x g for 5 min and

incubated for the indicated time points. The infection mixtures were then fixed in PBS

containing 4% paraformaldehyde, permeabilized in PBS containing 1% (vol/vol) Triton X-100

for 30 min, probed with mouse anti-polyUb (Enzo Life Biosciences, Cat# BML-PW8805-0500,

1:250) and rabbit anti- *L. pneumophila* followed by secondary probing with goat anti-rabbit

Alexa Fluor 594 (Invitrogen, Cat# 111-585-144, 1:500) and donkey anti-mouse Alexa Fluor 488

(Jackson ImmunoResearch, Cat# A-11012, 1:500). Hoescht 33342 (Life Technologies,

Cat#62249 1:10,000) was used to label nuclei.

Immunofluorescence of Rtn4-LCV colocalization

BMDMs were plated on glass coverslips at 1-2 x 10^5/well in 24-well plates. Cells were

infected at a multiplicity of infection (MOI) = 1, centrifuged at 200 x g for 5 min and incubated

for 1 hr. The infection mixtures were then fixed in PBS containing 4% paraformaldehyde,

permeabilized in PBS containing 1% (vol/vol) Triton X-100 for 30 min, probed rabbit anti-RTN4

(Lifespan Biosciences, Cat# LS-B6516, 1:500) and rat anti- *L. pneumophila*[73] followed by

secondary probing with goat anti-rabbit Alexa Fluor 488 (Jackson ImmunoResearch, Cat# 111-

545-003, 1:500) and donkey anti-rat Alexa Fluor 594 (Jackson ImmunoResearch, Cat# 712-585-

153, 1:500). Hoescht 33342 (Life Technologies, Cat#62249 1:10,000) was used to label nuclei.

Rtn4 Immunoprecipitations

For transfections preceding Rtn4 Immunoprecipitations (IP), HEK293T cells were plated

in DMEM medium containing 10% fetal calf serum at a density of 4 x 10^6 cells in a tissue

culture-treated 10cm dish. The next day, 12μg of pMT123 DNA (pHA::ubiquitin) was

transfected into cells using Lipofectamine 2000, following manufacturer's procedure (Life

Sciences). The mammalian HA::ubiquitin expression plasmid pMT123 was a kind gift from D.

Bohmann and S. Lippard[60, 74]. The next day, transfection medium was removed and replaced

with DMEM with 10μM MG132 (Calbiochem) at ~30-60min prior to challenge with *L.*

pneumophila at an MOI=10 for the indicated times [75, 76]. Post infection, cells were lifted and

washed in PBS, centrifuged at 4°C at 200 x g, and then cell pellets were immediately frozen on

liquid nitrogen and stored at -80°C until used[22].

For immunoprecipitations, anti-Rtn4 resin was generated by disuccinimidyl suberate

crosslinking with anti-Rtn4 (Nogo N-18, Santa Cruz sc-11027) to Protein A/G Plus™ resin at

2μg/μl of packed resin as described in manufacturer protocol (Pierce crosslink IP kit). Samples

were lysed in 1% Triton X-100 (20 mM Tris [pH 7], 150 mM NaCl, 5 mM $MgCl_2$) containing

protease inhibitor (Roche, Cat# 11697498001) with end-over-end rotation for 20 min at 4°C.

Cleared cell lysates were obtained by centrifugation at ≥14,000 x g for 10 min at 4°C, diluted

with an equal volume of detergent-free buffer, and mixed with washed resin (50% slurry). The

mixture was incubated at 4°C via end-over-end rotation for ≥ 4 hr, then washed ≥ 5X in the

buffer containing 0.1% Triton X-100 at 4°C.

For elution, Rtn4 resin in spin columns was incubated with 0.1M glycine (pH = 2.8) with

0.2% Triton X-100 for 5min, centrifuged, then eluate was reapplied to resin for additional 5 min

incubation at room temperature, centrifuged and neutralized with 0.5M Tris (pH=10.55)[22]. Eluate

bound to resin was resuspended with reducing SDS sample buffer, boiled, then fractionated by

SDS-PAGE coupled with immunoblot analyses.

Protein purification

Full-length *sdeC* genes were amplified by PCR and cloned into the bacterial expression

vector pQE-80L (Qiagen) with *BamHI* and *SacI* restriction sites to generate a 6xHis-SdeC-

StrepII fusion construct (Supplemental Table S1)[22]. Purified aliquots were stored at -80°C in

10% glycerol to minimize or eliminate freeze thaw cycle degradation.

Deubiquitinase assay in presence of Sde modification

His-tagged recombinant SdeC and its derivatives were bound to Ni-NTA (Thermo Fisher

Scientific, Cat# 88221) resin at 1 µg enzyme per 25µl of packed resin in 1X ART buffer (20mM

Tris 10mM NaCl, pH7.4) for 1 hr at 4°C with end-over-end rotation. The beads were washed 3X

with 1X ART buffer to remove non-adsorbed enzyme with microcentrifuge spin filters spun at

3000 x g at room temperature. After the final wash, each 25µl of pelleted resin was incubated

with 2µg of recombinant human K63-linked (R&D systems, Cat# UC-320) or K48-linked (R&D

Systems, Cat# UC-220) poly-ubiquitin and 500µM ε-NAD in 300 µl of 1X ART buffer for 2 hrs

with end-over-end gentle rotation at 37°C. After incubation, the SdeC or its derivatives-bound

resin were removed with microcentrifuge spin column filters, and the polyUb reaction mixture

was collected. This polyUb fraction was then incubated with either 1) 100 nM human

recombinant PolyHistidine-otubain 1(R&D systems, Cat# E-522B), 2) 50 nM recombinant

USP2 catalytic domain (R&D systems, Cat# E-504), 3) 50 nM recombinant PolyHistidine-

CYLD (R&D systems, Cat# E-556), or 50nM recombinant SdeC DUB (1-192) at 37°C in 1X

ART buffer for 2 hr. A fraction of the reaction was removed, terminated by the addition of

reducing sample buffer, and then heated to 50-55°C for 20-30min to avoid Ub chain aggregation.

Relative DUB activity was determined by immunoblot probing of SDS- SDS-PAGE fractionated

proteins using Image Studio software (LI-COR Biosciences) after 2 hr incubation by comparing

the efficiency of cleavage of modified Ub relative to unmodified.

Immunoblotting

Immunoblots were performed as described [77]. Samples were fractionated by SDS-PAGE

and transferred to nitrocellulose membranes. The membrane was blocked in 50 mM Tris-

buffered saline with 0.1% Tween-20 (TBST, pH 8.0) containing 4% nonfat milk for 1 hr at room

temperature and probed with primary antibodies: 1) anti-HA-probe (Santa Cruz Biotechnology,

Cat# sc-7392, 1:500), 2) anti-Ub (FK1; Santa Cruz Biotechnology, Cat# sc-8017) or anti-actin

(Sigma-Aldrich, Cat# A2066, 1:1,000) in TBST containing 2% BSA at 4°C overnight. After

washing 3X with TBST, the membranes were incubated with secondary antibodies: donkey

IRDye 680RD anti-mouse (LI-COR Biosciences, Cat# 926-68072, 1:20,000), Goat IRDye

680RD anti-rabbit (LI-COR Biosciences, Cat# 926-68071, 1:20,000), and/or donkey

IRDye800CW anti-mouse (LI-COR Biosciences, Cat# 926-32212, 1:20,000), goat IRDye

800CW α-rabbit (LI-COR Biosciences, Cat# 926-32211, 1:20,000) for 45 min at room

temperature. Capture and analysis were performed using Li-Cor Odyssey CLX scanner and

Image Studio software (LI-COR Biosciences).

Bead-binding assay for adaptors association with polyUb post Sde-mediated modification

of Ub

His-tagged recombinant full-length SdeC derivatives were adsorbed to Ni-NTA (Thermo

Fisher Scientific, Cat# 88221) resin at 1μg enzyme per 25 μl of packed resin in 1X ART buffer

for 1 hr at 4°C with end-over-end rotation. The SdeC adsorbed resin was washed 3X with 1X

ART buffer to remove nonadsorbed enzyme with microcentrifuge spin filters centrifuged at 3000

x g at room temperature. After the final SdeC resin wash, each 25 μl pelleted resin was

resuspended with 4μg of recombinant human homotypic-linked polyubiquitin chains Ub_{3-7} (K63

or K48, 4μg/600μl reaction volume, Boston Biochem, R&D) and 500μM ε-NAD in 1X ART

buffer for 2 hrs with gentle end-over-end rotation at 37°C. During incubation of SdeC and

polyUb chains, 1μg recombinant PolyHis-p62 was adsorbed to 5 μl pre-equilibrated packed Ni-

NTA resin (Thermo Fisher Scientific, Cat# 88221) via 1 hr, end-over-end rotation at 4°C in low

adhesion 1.5 ml microcentrifuge tubes. Polyubiquitin chains were then separated from SdeC by

collection of SdeC resin in a microcentrifuge column spin filter and then the polyUb fraction was

incubated with recombinant PolyHis-p62 on Ni-NTA resin for 1 hr at room temperature with

end-over-end rotation. The resin was washed 3-5X with 50mM Tris 0.1% BSA (vol/vol) pH7.5

at room temperature, then resin having adsorbed proteins and bound polyUb chains were eluted

from the Ni-NTA beads with 250 mM imidazole diluted in 50 mM Tris 0.1% BSA (vol/vol)

pH7.5. Samples were then analyzed by SDS-PAGE followed by immunoblot.

Preparation of Sde-modified ubiquitin derivatives.

For modification of Ub, 100 µg of K63-linked Ub tetramer (R&D Systems, Cat# UCB-

310 or South Bay Bio, SBB-UP0073) or monomeric Ub (R&D Systems, Cat# U-100H) were

incubated together with 100 µM β-NAD and 20 nM SdeC variants (WT, C118S/DUB⁻,

E859A/ART⁻ and H416A/PDE⁻) in 250 µl of 1X ART buffer at 37°C for 1 h. For DUB inhibitor

pretreatment, 1 µM ubiquitin-propargylamide (R&D Systems, Cat# U-214) was incubated with

100 nM SdeC variants at room temperature for 30 min before adding to Ub4 (final concentration,

20 nM SdeC in 1X ART buffer). To remove the SdeC, 10 µl of a 50% slurry of Ni-NTA agarose

resin (Thermo Fisher Scientific, Cat# 88221) was washed three times with 1X ART buffer, then

added to the Ub-SdeC reaction for another 1hr with end-over-end rotation at 37°C. For removal

of SdeC enzyme, the samples were centrifuged at 1000 x g for 2 min in a microcentrifuge spin

filter column. The supernatant was then desalted using a NAP-5 column (Thermo Fisher

Scientific, Cat# 45-000-151) and lyophilized with a Labconco Freezone12. Samples were

resuspended in Ultrapure water to a final protein concentration of 1 mg/ml.

LC-MS analysis of modified Ub$_4$.

Reversed-phase chromatography and mass spectrometry was performed on an Agilent
1260 Infinity LC system in line with an Agilent 6530 Q-TOF. Intact Ub$_4$ samples were diluted in
water and injected onto a Zorbax 300 SB-C8 Rapid Resolution HD 1.8 μm column (2.1 x 100
mm, Agilent) and were eluted with a water:acetonitrile gradient mobile phase with 0.1% formic
acid (0.400 mL/min; 95% - 20% over 26 min). The mass spectrometer was utilized in positive
mode with a dual electrospray ionization (ESI) source. MS spectra were acquired using the
following settings: ESI capillary voltage, 4500 V; fragmentor, 250 V; gas temperature, 325°C;
gas rate, 12.5 L/min; nebulizer, 50 psig. Data was acquired at rate of 5 spectra per second and
scan range of 100 – 3000 m/z.

For trypsin digestion, Ub$_4$ samples were incubated at 95 degrees in 1:1 water:t-butanol
for 35 min, then allowed to cool to room temperature. DTT was added to a concentration of 3
mM, trypsin was added in a ratio of 25:1 Ub$_4$:trypsin and incubated overnight. The reaction was
then diluted in dH$_2$O for mass spectrometry. Following tryptic digestion, peptide fragments were
injected onto an AdvanceBio Peptide 2.7 μm column (2.1 x 150 mm, Agilent) and were eluted
with a water:acetonitrile gradient mobile phase with 0.1% formic acid (0.400 ml/min; 95% - 5%
over 19 min). MS spectra were acquired using the following settings: ESI capillary voltage, 4000
V; fragmenter, 150 V; gas temperature, 325°C; gas rate, 12 L/min; nebulizer, 40 psig. Data were
acquired at a rate = 5 spectra per second and scan range of 300 – 3000 m/z. MS/MS spectra were
acquired using the following settings: ESI capillary voltage, 4000 V; fragmentor, 150 V; gas
temperature, 325°C; gas rate 12 l/min; nebulizer, 40 psig. MS/MS was acquired at 2 spectra per
second at a mass range of 100 – 3000 m/z, with stringency set to a medium isolation width. After

identification, precursor ions were subjected to iterative rounds of collision-induced dissociation

in the collision chamber and subsequent mass identification. A ramped collision energy was used

with a slope of 3.6 and offset of -4.8 as well as a slope of 3 and offset of 2.

Following acquisition, analysis was completed using multiple programs. Agilent

MassHunter Qualitative Analysis (v. 7.00) was used to generate mass spectra, and extracted ion

chromatograms (EIC). Agilent MassHunter Bioconfirm (v. B.010.00) was used to identify and

match tryptic fragments of the Ub_4 and pR modified Ub_4 proteins, and identify b and y ion

fragmentation from combined MS/MS spectra. For the control mono-Ub incubated in the

presence or absence of SdeC, n=1 for each treatment. For Ub_4 in absence of SdeC, n=2

biological replicates, from two different suppliers. For Ub_4 incubated with SdeC, n=2 technical

replicates for intact protein and n=7 technical replicates for trypsin digested protein. MS data

were deposited in ProteomeXchange (http://www.proteomexchange.org/), accession number

MSV000094791.

SPR analysis of p62 binding to ubiquitin.

The binding kinetics between p62 and modified Ub_4 was determined by surface plasmon

resonance (SPR) using a Biacore T200 system, with a runner buffer of HEPES Buffered Saline

(HBS; 10 mM HEPES (pH =7.4), 150 mM NaCl) containing 30 μM of EDTA. 6xHis-tagged p62

was captured onto a Series S NTA sensor chip following manufacturer's recommendations

(Cytiva, Cat# 28994951). Briefly, 0.5 mM $NiCl_2$ solution was injected at a flow rate of 10 μl/min

for 60 seconds onto the experimental flow cell, followed by the injection of His-p62 (200 nM) at

5 ul/min for 420 seconds. Ub_4 at various concentrations, that had been previously treated with

SdeC derivatives, was injected into the flow cells at a rate of 30 μl/min for 180 seconds,

followed by a 300 seconds dissociation phase. Regeneration of the surface was performed by two

injections of 350 mM EDTA (30 ul/min, 60 seconds) followed by an injection of 6M guanidine

hydrochloride with 50 mM NaCl (30 ul/min, 30 seconds). The binding kinetics were determined

with Biacore Evaluation software (v3) using double referenced sensorgrams and 1:1 binding for

the fitting model.

Immunofluorescence of p62 at the LCV

674   BMDMs were plated on glass coverslips at 1-2 x10^5/well in 24-well plates. Cells were

challenged at a multiplicity of infection (MOI) = 2, centrifuged at 200 x g for 5 min, and

incubated for the indicated time points. For 180 min infections, the cells were washed 3X in PBS

at 60 min post-infection to remove non-internalized bacteria, then fresh culture media was added.

At the infection conclusion, all cells were washed 3X in PBS, fixed in PBS containing 4%

(wt/vol) paraformaldehyde, followed by permeabilization with ice-cold 100% methanol for 20

seconds. Coverslips were then washed 3X in PBS and blocked in PBS containing 2-4% BSA for

at least 30 min. Cells were then stained in PBS with rat anti-*L. pneumophila* and rabbit anti-

p62/SQSTM (Abcam, Cat# 109012, 1:400) for 1 hr and detected with donkey anti-rat Alexa

Fluor 594 (Jackson ImmunoResearch, Cat# 712-585-153, 1:500) and goat anti-rabbit Alexa

Fluor 488 (Jackson ImmunoResearch, Cat# 111-545-003, 1:500). Hoechst 33342 was used to

label DNA.

Image analysis

688   Representative images were taken using Zeiss Axiovert or Nikon inverted phase

fluorescence microscopes, and image enhanced in Photoshop™ (Adobe), using linear

corrections. For quantification of total polyUb intensity, Volocity software (PerkinElmer) was

used. ROIs (regions of interest, 14 x 12 μm; oval) were set around LCVs, and pixel intensities

were measured and subtracted by background intensity. For quantification of total p62 intensity,

we set ROIs (0.3 x 0.42 inches; oval) around LCVs. Mean p62 intensity/pixel was measured in

each ROI and subtracted by background intensity/pixel using Fiji image analysis software[78].

Data Availability Statement.

Data and images that support the findings of this study are available in Source Data File. Mass

Spectrometry data were deposited in ProteomeXchange (http://www.proteomexchange.org/),

accession number MSV000094791.   Source data are provided with this paper.

Statement on Samples

All measurements were taken from distinct samples. The following panels analyzed data from

the same set of samples: 5C and 5D; 5E and 5F; 5G and 5H; 5J and 5K; 6A and 6B. Panel 5L is a

summary of panels in Fig. 5, as noted in Figure Legend.

References

709   1.   Cunha, B.A., Wu, G. & Raza, M. Clinical Diagnosis of Legionnaire's Disease: Six
710   Characteristic Clinical Predictors. *Am J Med* **128**, e21-22 (2015).
711

712   2.   Cunha, B.A., Burillo, A. & Bouza, E. Legionnaires' disease. *Lancet* **387**, 376-385
713   (2016).
714

715   3.   Safdar, N., Crnich, C.J. & Maki, D.G. The pathogenesis of ventilator-associated
716   pneumonia: its relevance to developing effective strategies for prevention. *Respir*
717   *Care* **50**, 725-739; discussion 739-741 (2005).
718

719   4.   Horwitz, M.A. & Silverstein, S.C. Interaction of the Legionnaires' disease bacterium
720   (*Legionella pneumophila*) with human phagocytes. I. *L. pneumophila* resists killing by
721   polymorphonuclear leukocytes, antibody, and complement. *J Exp Med* **153**, 386-397
722   (1981).
723

724   5.   Rowbotham, T.J. Isolation of *Legionella pneumophila* from clinical specimens via
725   amoebae, and the interaction of those and other isolates with amoebae. *J Clin Pathol*
726   **36**, 978-986 (1983).
727

728   6.   Abu Kwaik, Y. The phagosome containing *Legionella pneumophila* within the
729   protozoan *Hartmannella vermiformis* is surrounded by the rough endoplasmic
730   reticulum. *Appl Environ Microbiol* **62**, 2022-2028 (1996).
731

732   7.   Swanson, M.S. & Isberg, R.R. Association of *Legionella pneumophila* with the
733   macrophage endoplasmic reticulum. *Infection and immunity* **63**, 3609-3620 (1995).
734

735   8.   Kagan, J.C. & Roy, C.R. *Legionella* phagosomes intercept vesicular traffic from
736   endoplasmic reticulum exit sites. *Nat Cell Biol* **4**, 945-954 (2002).
737

738   9.   Horwitz, M.A. Characterization of avirulent mutant *Legionella pneumophila* that
739   survive but do not multiply within human monocytes. *J Exp Med* **166**, 1310-1328
740   (1987).
741

742   10.   Marra, A., Blander, S.J., Horwitz, M.A. & Shuman, H.A. Identification of a *Legionella*
743   *pneumophila* locus required for intracellular multiplication in human macrophages.
744   *Proc Natl Acad Sci U S A* **89**, 9607-9611 (1992).
745

746   11.   Berger, K.H. & Isberg, R.R. Two distinct defects in intracellular growth
747   complemented by a single genetic locus in *Legionella pneumophila*. *Molecular*
748   *microbiology* **7**, 7-19 (1993).
749

750   12.   Burstein, D. *et al.* Genomic analysis of 38 *Legionella* species identifies large and
751   diverse effector repertoires. *Nat Genet* **48**, 167-175 (2016).
752
753   13.   Gomez-Valero, L. *et al.* More than 18,000 effectors in the *Legionella* genus genome
754   provide multiple, independent combinations for replication in human cells. *Proc*
755   *Natl Acad Sci U S A* **116**, 2265-2273 (2019).
756
757   14.   Qiu, J. & Luo, Z.Q. *Legionella* and *Coxiella* effectors: strength in diversity and activity.
758   *Nat Rev Microbiol* **15**, 591-605 (2017).
759
760   15.   Creasey, E.A. & Isberg, R.R. The protein SdhA maintains the integrity of the
761   *Legionella*-containing vacuole. *Proc Natl Acad Sci U S A* **109**, 3481-3486 (2012).
762
763   16.   Steiner, B., Weber, S. & Hilbi, H. Formation of the *Legionella*-containing vacuole:
764   phosphoinositide conversion, GTPase modulation and ER dynamics. *Int J Med*
765   *Microbiol* **308**, 49-57 (2018).
766
767   17.   Gaspar, A.H. & Machner, M.P. VipD is a Rab5-activated phospholipase A1 that
768   protects *Legionella pneumophila* from endosomal fusion. *Proc Natl Acad Sci U S A*
769   **111**, 4560-4565 (2014).
770
771   18.   Belyi, Y. *et al. Legionella pneumophila* glucosyltransferase inhibits host elongation
772   factor 1A. *Proc Natl Acad Sci U S A* **103**, 16953-16958 (2006).
773
774   19.   Jeong, K.C., Sexton, J.A. & Vogel, J.P. Spatiotemporal regulation of a *Legionella*
775   *pneumophila* T4SS substrate by the metaeffector SidJ. *PLoS Pathog* **11**, e1004695
776   (2015).
777
778   20.   Qiu, J. *et al.* Ubiquitination independent of E1 and E2 enzymes by bacterial effectors.
779   *Nature* **533**, 120-124 (2016).
780
781   21.   Bhogaraju, S. *et al.* Phosphoribosylation of Ubiquitin Promotes Serine Ubiquitination
782   and Impairs Conventional Ubiquitination. *Cell* **167**, 1636-1649 e1613 (2016).
783
784   22.   Kotewicz, K.M. *et al.* A Single *Legionella* Effector Catalyzes a Multistep Ubiquitination
785   Pathway to Rearrange Tubular Endoplasmic Reticulum for Replication. *Cell Host*
786   *Microbe* **21**, 169-181 (2017).
787
788   23.   Song, L. *et al.* The *Legionella* Effector SdjA Is a Bifunctional Enzyme That Distinctly
789   Regulates Phosphoribosyl Ubiquitination. *mBio* **12**, e0231621 (2021).
790
791   24.   Sulpizio, A. *et al.* Protein polyglutamylation catalyzed by the bacterial calmodulin-
792   dependent pseudokinase SidJ. *Elife* **8** (2019).
793
794   25.   Bhogaraju, S. *et al.* Inhibition of bacterial ubiquitin ligases by SidJ-calmodulin
795   catalysed glutamylation. *Nature* **572**, 382-386 (2019).

797 26. Black, M.H. *et al.* Bacterial pseudokinase catalyzes protein polyglutamylation to
798   inhibit the SidE-family ubiquitin ligases. *Science* **364**, 787-792 (2019).
799

800 27. Wan, M. *et al.* Deubiquitination of phosphoribosyl-ubiquitin conjugates by
801   phosphodiesterase-domain-containing *Legionella* effectors. *Proc Natl Acad Sci U S A*
802   **116**, 23518-23526 (2019).
803

804 28. Shin, D. *et al.* Regulation of Phosphoribosyl-Linked Serine Ubiquitination by
805   Deubiquitinases DupA and DupB. *Mol Cell* **77**, 164-179 e166 (2020).
806

807 29. Akturk, A. *et al.* Mechanism of phosphoribosyl-ubiquitination mediated by a single
808   *Legionella* effector. *Nature* **557**, 729-733 (2018).
809

810 30. Kalayil, S. *et al.* Insights into catalysis and function of phosphoribosyl-linked serine
811   ubiquitination. *Nature* **557**, 734-738 (2018).
812

813 31. Dong, Y. *et al.* Structural basis of ubiquitin modification by the *Legionella* effector
814   SdeA. *Nature* **557**, 674-678 (2018).
815

816 32. Sheedlo, M.J. *et al.* Structural basis of substrate recognition by a bacterial
817   deubiquitinase important for dynamics of phagosome ubiquitination. *Proc Natl Acad*
818   *Sci U S A* **112**, 15090-15095 (2015).
819

820 33. Zhang, M. *et al.* Members of the *Legionella pneumophila* Sde family target tyrosine
821   residues for phosphoribosyl-linked ubiquitination. *RSC Chem Biol* **2**, 1509-1519
822   (2021).
823

824 34. Liu, Y. *et al.* Serine-ubiquitination regulates Golgi morphology and the secretory
825   pathway upon *Legionella* infection. *Cell Death Differ* **28**, 2957-2969 (2021).
826

827 35. Kim, S. & Isberg, R.R. The Sde phosphoribosyl-linked ubiquitin transferases protect
828   the *Legionella pneumophila* vacuole from degradation by the host. *Proc Natl Acad Sci*
829   *U S A* **120**, e2303942120 (2023).
830

831 36. Bruckert, W.M. & Abu Kwaik, Y. Lysine11-Linked Polyubiquitination of the AnkB F-
832   Box Effector of *Legionella pneumophila*. *Infect Immun* **84**, 99-107 (2016).
833

834 37. Ivanov, S.S. & Roy, C.R. Modulation of ubiquitin dynamics and suppression of DALIS
835   formation by the *Legionella pneumophila* Dot/Icm system. *Cell Microbiol* **11**, 261-
836   278 (2009).
837

838 38. Horenkamp, F.A. *et al. Legionella pneumophila* subversion of host vesicular
839   transport by SidC effector proteins. *Traffic* **15**, 488-499 (2014).
840

841   39.   Hsu, F. *et al.* The *Legionella* effector SidC defines a unique family of ubiquitin ligases
842   important for bacterial phagosomal remodeling. *Proc Natl Acad Sci U S A* **111**,
843   10538-10543 (2014).
844

845   40.   Dorer, M.S., Kirton, D., Bader, J.S. & Isberg, R.R. RNA interference analysis of
846   *Legionella* in Drosophila cells: exploitation of early secretory apparatus dynamics.
847   *PLoS Pathog* **2**, e34 (2006).
848

849   41.   Tomaskovic, I., Gonzalez, A. & Dikic, I. Ubiquitin and *Legionella*: From bench to
850   bedside. *Semin Cell Dev Biol* (2022).
851

852   42.   Puvar, K. *et al.* Ubiquitin Chains Modified by the Bacterial Ligase SdeA Are Protected
853   from Deubiquitinase Hydrolysis. *Biochemistry* **56**, 4762-4766 (2017).
854

855   43.   Boyle, K.B. & Randow, F. The role of 'eat-me' signals and autophagy cargo receptors
856   in innate immunity. *Curr Opin Microbiol* **16**, 339-348 (2013).
857

858   44.   von Muhlinen, N. *et al.* An essential role for the ATG8 ortholog LC3C in antibacterial
859   autophagy. *Autophagy* **9**, 784-786 (2013).
860

861   45.   Mitchell, G. & Isberg, R.R. Innate Immunity to Intracellular Pathogens: Balancing
862   Microbial Elimination and Inflammation. *Cell Host Microbe* **22**, 166-175 (2017).
863

864   46.   Choy, A. *et al.* The *Legionella* effector RavZ inhibits host autophagy through
865   irreversible Atg8 deconjugation. *Science* **338**, 1072-1076 (2012).
866

867   47.   Arasaki, K. & Tagaya, M. *Legionella* blocks autophagy by cleaving STX17 (syntaxin
868   17). *Autophagy* **13**, 2008-2009 (2017).
869

870   48.   Rolando, M. *et al. Legionella pneumophila* S1P-lyase targets host sphingolipid
871   metabolism and restrains autophagy. *Proc Natl Acad Sci U S A* **113**, 1901-1906
872   (2016).
873

874   49.   Omotade, T.O. & Roy, C.R. *Legionella pneumophila* Excludes Autophagy Adaptors
875   from the Ubiquitin-Labeled Vacuole in Which It Resides. *Infection and immunity* **88**
876   (2020).
877

878   50.   Wan, M. *et al.* Phosphoribosyl modification of poly-ubiquitin chains at the
879   *Legionella*-containing vacuole prohibiting autophagy adaptor recognition. *Submitted*
880   (2023).
881

882   51.   Isogai, S. *et al.* Crystal structure of the ubiquitin-associated (UBA) domain of p62
883   and its interaction with ubiquitin. *J Biol Chem* **286**, 31864-31874 (2011).
884

885   52.   Johansen, T. & Lamark, T. Selective autophagy mediated by autophagic adapter
886   proteins. *Autophagy* **7**, 279-296 (2011).

888   53.   Long, J. *et al.* Ubiquitin recognition by the ubiquitin-associated domain of p62
889   involves a novel conformational switch. *J Biol Chem* **283**, 5427-5440 (2008).

891   54.   Long, J. *et al.* Dimerisation of the UBA domain of p62 inhibits ubiquitin binding and
892   regulates NF-kappaB signalling. *J Mol Biol* **396**, 178-194 (2010).

894   55.   Tan, X.L. *et al.* Sortase-mediated chemical protein synthesis reveals the bidentate
895   binding of bisphosphorylated p62 with K63 diubiquitin. *Chem Sci* **8**, 6881-6887
896   (2017).

898   56.   Gan, N. *et al.* Regulation of phosphoribosyl ubiquitination by a calmodulin-
899   dependent glutamylase. *Nature* **572**, 387-391 (2019).

901   57.   Ge, J. *et al.* Phosphoribosyl-linked serine ubiquitination of USP14 by the SidE family
902   effectors of *Legionella* excludes p62 from the bacterial phagosome. *Cell Rep* **42**,
903   112817 (2023).

905   58.   Bhogaraju, S. & Dikic, I. Cell biology: Ubiquitination without E1 and E2 enzymes.
906   *Nature* **533**, 43-44 (2016).

908   59.   Kozlov, G. *et al.* Structural basis of ubiquitin recognition by the ubiquitin-associated
909   (UBA) domain of the ubiquitin ligase EDD. *J Biol Chem* **282**, 35787-35795 (2007).

911   60.   Ensminger, A.W. & Isberg, R.R. E3 ubiquitin ligase activity and targeting of BAT3 by
912   multiple *Legionella pneumophila* translocated substrates. *Infection and immunity* **78**,
913   3905-3919 (2010).

915   61.   Hubber, A., Kubori, T. & Nagai, H. Modulation of the ubiquitination machinery by
916   *Legionella*. *Curr Top Microbiol Immunol* **376**, 227-247 (2013).

918   62.   Nagai, H. & Kubori, T. Purification and characterization of *Legionella* U-box-type E3
919   ubiquitin ligase. *Methods Mol Biol* **954**, 347-354 (2013).

921   63.   Liu, S. *et al.* Interplay between bacterial deubiquitinase and ubiquitin E3 ligase
922   regulates ubiquitin dynamics on *Legionella* phagosomes. *Elife* **9** (2020).

924   64.   Ong, S.Y. *et al.* Genome-wide genetic screen identifies host ubiquitination as
925   important for *Legionella pneumophila* Dot/Icm effector translocation. *Cell Microbiol*
926   **23**, e13368 (2021).

928   65.   Goodall, E.A., Kraus, F. & Harper, J.W. Mechanisms underlying ubiquitin-driven
929   selective mitochondrial and bacterial autophagy. *Mol Cell* **82**, 1501-1513 (2022).

931   66.   Sharma, V., Verma, S., Seranova, E., Sarkar, S. & Kumar, D. Selective Autophagy and
932   Xenophagy in Infection and Disease. *Front Cell Dev Biol* **6**, 147 (2018).

934 67. Faucher, S.P., Mueller, C.A. & Shuman, H.A. *Legionella pneumophila* Transcriptome
935   during Intracellular Multiplication in Human Macrophages. *Front Microbiol* **2**, 60
936   (2011).
937

938 68. Jeong, K.C., Sutherland, M.C. & Vogel, J.P. Novel export control of a *Legionella*
939   Dot/Icm substrate is mediated by dual, independent signal sequences. *Mol Microbiol*
940   **96**, 175-188 (2015).
941

942 69. Bardill, J.P., Miller, J.L. & Vogel, J.P. IcmS-dependent translocation of SdeA into
943   macrophages by the *Legionella pneumophila* type IV secretion system. *Molecular*
944   *microbiology* **56**, 90-103 (2005).
945

946 70. O'Connor, T.J., Boyd, D., Dorer, M.S. & Isberg, R.R. Aggravating genetic interactions
947   allow a solution to redundancy in a bacterial pathogen. *Science* **338**, 1440-1444
948   (2012).
949

950 71. Berger, K.H., Merriam, J.J. & Isberg, R.R. Altered intracellular targeting properties
951   associated with mutations in the *Legionella pneumophila* dotA gene. *Molecular*
952   *microbiology* **14**, 809-822 (1994).
953

954 72. Byrne, B. & Swanson, M.S. Expression of *Legionella pneumophila* virulence traits in
955   response to growth conditions. *Infection and immunity* **66**, 3029-3034 (1998).
956

957 73. Haenssler, E., Ramabhadran, V., Murphy, C.S., Heidtman, M.I. & Isberg, R.R.
958   Endoplasmic Reticulum Tubule Protein Reticulon 4 Associates with the *Legionella*
959   *pneumophila* Vacuole and with Translocated Substrate Ceg9. *Infection and immunity*
960   **83**, 3479-3489 (2015).
961

962 74. Treier, M., Staszewski, L.M. & Bohmann, D. Ubiquitin-dependent c-Jun degradation
963   in vivo is mediated by the delta domain. *Cell* **78**, 787-798 (1994).
964

965 75. Losick, V.P., Haenssler, E., Moy, M.Y. & Isberg, R.R. LnaB: a *Legionella pneumophila*
966   activator of NF-kappaB. *Cellular microbiology* **12**, 1083-1097 (2010).
967

968 76. Lipo, E. *et al.* 5' Untranslated mRNA Regions Allow Bypass of Host Cell Translation
969   Inhibition by *Legionella pneumophila*. *Infection and immunity* **90**, e0017922 (2022).
970

971 77. Derre, I. & Isberg, R.R. LidA, a translocated substrate of the *Legionella pneumophila*
972   type IV secretion system, interferes with the early secretory pathway. *Infection and*
973   *immunity* **73**, 4370-4380 (2005).
974

975 78. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat*
976   *Methods* **9**, 676-682 (2012).
977

Acknowledgements. KMK was supported by NIH training grant T32GM007310. This

work was supported by NIAID grants R01AI113211 and R01AI146245 to RRI and NIGMS

grant R01GM132422 to RAS. Panels 4A and 4B were used under terms of Creative Commons.

We thank Drs Kevin Manera for review of the manuscript and Dr. Yuxin Mao for

communication of results before publication.

Author Contributions. KMK and MZ designed, performed and analyzed experiments

as well as contributed to writing of the manuscript. SK performed and analyzed experiments.

MSM designed, performed and analyzed experiments and contributed to writing of manuscript.

ARC designed, performed and analyzed experiments as well as contributed to writing of

manuscript. AT performed and analyzed experiments. RAS directed research, designed and

analyzed experiments and contributed to writing of manuscript. RRI directed research, designed

and analyzed experiments and contributed to writing of manuscript.

993
994   **Competing Interest Statement.** The authors declare no competing interests.
995
996
997
998

999   **Figure Legends**

1000

Figure 1. The Sde DUB domain is required for efficient phosphoribose-ubiquitination of

Rtn4.

(**A**) Domain structure of Sde family proteins. Catalytically inactive point mutations are shown in

red. (**B**) Percent poly-Ub positive LCVs of *L. pneumophila* strains at noted timepoints post-

infection. (**C**) Quantification of Rtn4-positive LCVs. BMDMs were challenged with indicated

strains for the noted infection times, followed by fixation, permeabilization with 1% Triton X-

100 and probing as described in Methods. 0 MPI was immediately after 5 min centrifugation of

bacteria onto BMDM. Noted strains are wild type, Lp02; Δ*sde*, Δ*sidE*Δ*sdeC*Δ*sdeB-A*; Vector or

pV, pJB908att-empty (Supplemental Table S1). For each experiment, n> 80 LCVs (B) or n>50

LCVs (C) per experiment were evaluated and data were determined from 3 biological replicates

(mean ± SEM; two-way ANOVA with Tukey's multiple comparison **(B, C)**; ns (non-

significant); exact P values are displayed over data, and are found in Source Data File. For each

replicate, n value is shown in Source Data File. **(D-I):** Representative micrographs of Rtn4

recruitment, scale bar = 5 µm. Scalebar determined for each image independently and pasted on

each image. Macrophages were challenged with either WT containing pV or noted mutant strains

for 1 hr, fixed, permeabilized and probed with anti-*L. pneumophila* (Alexa Fluor 594 secondary,

red), anti-Rtn4 (Alexa Fluor 488 secondary, green), and Hoechst (nucleus, blue). **(J)** Cartoon of

strategy to identify pR-Ub modified Rtn4. **(K)** Immunoblot image of anti-Rtn4

immunoprecipitates by immunoprobing with anti-HA. To right of immunoblots are Rtn4

isoforms and modification status. HEK293T cells were challenged with noted *L. pneumophila*

strains for either 10 or 180 mins. Modified Rtn4 substrates were immunoprecipitated using

crosslinked anti-Rtn4, fractioned on 7.5% SDS-PAGE, and probed with anti-HA. Lanes: WT,

Lp02; vector, Δ*sde*; p*sdeA*, Δ*sde* expressing SdeA; p*sdeA C118S*, Δ*sde* expressing SdeA DUB

mutant; p*sdeB*, Δ*sde* expressing SdeB; p*sdeB C118S*, Δ*sde* expressing SdeB DUB mutant;

MOCK, uninfected. Masses are apparent molecular weights as noted in kDal. Source data are

provided as a Source Data file.

1027

1028 **Figure 2. The ART domain blocks DUB activity and promotes hyper-polyubiquitination of**

1029 **the LCV.**

1030 (**A**). SdeC WT or its catalytic mutant derivatives (1µg) were adsorbed to Ni-NTA resin for 1 hr

1031 at 4°C, then incubated with either K63 or K48-linked polyUb$_{3-7}$ (2µg) for 2 hrs at 37°C. SdeC

1032 resin was removed and polyUb$_{3-7}$ was then incubated with: human recombinant Polyhistidine-

1033 otubain 1, isoform 1 (100 nM); recombinant USP2 catalytic domain (50 nM); recombinant

1034 Polyhistidine-CYLD (50 nM); or recombinant SdeC DUB CD 1-192 (50 nM) at 37°C for 2 hrs.

1035 Cleavage was monitored by immunoblotting with anti-Ub (FK1). Shown are data from one of

1036 two independent replicates performed on separate days with similar results. Molecular weights

1037 are shown to left of each blot using protein standards of apparent molecular masses 25 kDal and

1038 75 kDal. (**B**) Quantification of polyUb intensity associated with individual LCVs of the noted

1039 strains at 20 MPI. Data shown are means $\pm$ 95% confidence intervals, analyzed by one-way

1040 ANOVA with Dunnett's multiple comparison. Data are pooled from 3 biological replicates. WT,

1041 n=21; C118S, n=23; E859, n= 17; H416, n=28.   The dotted lines represent background level of

1042 polyUb intensity about LCVs**. (C)** PolyUb intensity of LCVs harboring Δ*sde* expressing SdeC

1043 PDE⁻ (H416A) mutant at 20 or 60 MPI. Data are shown in median $\pm$ 25%ile; Mann-Whitney 2-

1044 tailed test. The dotted lines represent background level of polyUb intensity about LCVs. Data are

1045 pooled from 3 biological replicates. 20 MPI, n=28; 60 MPI n=25. All P values are found in

1046 Source Data File. **(D-H)** Examples of polyUb-positive LCVs. Shown are images from one of

1047 three biological replicates with similar results. BMDMs were challenged by 5 min centrifugation

1048 at an MOI of 1, incubated with noted *L. pneumophila* strains, fixed, permeabilized with 1%

1049 Triton X100, and probed with anti-polyUb (Alexa Fluor 488 secondary, green), anti-*L.*

1050 *pneumophila* (Alexa Fluor 594 secondary, red), and Hoechst (blue). Strains used: WT, Lp02;

1051 *Δsde*, *ΔsidE ΔsdeC ΔsdeB-A; Δsde psdeC*$_{WT}$, Δ*sde* expressing SdeC WT; *Δsde psdeC*$_{C118S}$, Δ*sde*

1052 expressing SdeC DUB mutant; *Δsde psdeC*$_{E859A}$, Δ*sde* expressing SdeC ART mutant; *Δsde*

1053 *psdeC*$_{H416A}$, Δ*sde* expressing SdeC PDE mutant. Scale bar: 5μm. Source data are provided as a

1054 Source Data file.

1055

1056

1057 **Figure 3. Phosphoribosyl modification of Ub₄ occurs at Arg42.**

(A). SdeC(DUB⁻) incubation with Ub$_4$ results in a mass increase of 848.21 AMU. Samples were

subjected to LC-MS analysis and the deconvoluted masses of the peaks for each sample are

displayed. Top: untreated Ub$_4$. Bottom: Ub$_4$ incubated with SdeC(DUB⁻) and NAD. **(B)**. Sde

modification of Ub$_4$ occurs exclusively on Arg42. Representative extracted ion chromatograms

(EICs) are shown for the pR-modified R42 tryptic fragment, as well as tryptic fragments

containing R54 and R72. The unmodified R42 fragment could not be found in SdeC-treated

samples**.** **(C).** MS/MS analysis of the pR-modified tryptic fragment. Observed diagnostic ions

that confirm specificity to R42 are shown in bold. Blue: b ions. Red: y ions. Source data are

displayed. Underlying data are available n ProteomeXchange repository

(www.proteomexchange.org/).

1068

1069

Figure 4. Sde-mediated modification of polyUb prevents its recognition by p62.

(A) Space filling model of Ub. R42 residue (blue letter) and I44 residue are indicated with blue

arrows (from reference[53, 59]).**(B)** Interface residues between UBA domain and Ub, showing

possible involvement of Ub R42 in interacting with UBA domain (from reference[53, 59]). **(C, D)**

Ub modification at R42 blocks p62 binding (Methods). Ni-NTA-p62 was incubated with Ub$_{3-7}$

that had been treated with SdeC WT or its catalytic mutant derivatives and allowed to bind (In).

Unbound Ub$_{3-7}$ was removed (FT), the beads were washed, and then eluted with 250mM

imidazole (E: elution). The p62-bound poly-Ub in the eluate was fractionated by SDS-PAGE

followed by probing with anti-Ub. Relative loading: In, input (2.5%); FT, flow-through (2.5%);

E, eluate (25%). Molecular weight markers are from protein standards of 25 kDal and 75 kDal

apparent molecular weights. Shown are data from one of two independent experiments. **(E)**

Surface plasmon resonance (SPR) quantitation of p62 binding to Ub derivatives. Ub$_1$ or Ub$_4$ was

incubated with SdeC WT or its derivatives immobilized on Ni-NTA resin, the supernatant

containing modified Ub derivatives was incubated with 6xHis-tagged p62 bound to a Ni-NTA

1084 chip, and binding affinity was measured by plasmon resonance. **(F, G)** Sensorgrams of Ub_4 or

1085 Ub_1 binding to p62. Binding of Ub_4 to p62 yields a $K_D = 0.97 \times 10^{-7}$ M. **(H-K)** Sensorgrams of

1086 Ub_4, modified as noted in panels (red balls: phosphoribosyl addition; green balls: ADP-ribosyl

1087 addition). Reactions were formed in the presence of Ub-propargylamide (DUB inhibitor). All

1088 sensorgrams are source data. All other data are available as a Source Data file. Source data are

1089 provided as a Source Data file.

1090

1091 **Figure 5. Transient blockade of p62 recruitment to the LCV in the presence of Sde family**

1092 **members.**

1093 **(A-B)** Examples of punctate (A) or enveloped (B) p62 morphology localized around LCVs after

1094 challenge of BMDMs with noted *L. pneumophila* strains. The scale bar represents 10 μm. **(C, E,**

1095 **G, J)** The Percentage of circumferential p62 associated with LCVs at 0 (immediate bacterial

1096 contact; C) or 20 (E) or 60 (G) or 180 (J) MPI. 100 LCVs per replicate were counted in n=3

1097 biological replicates (mean ± SEM; one-way ANOVA with Dunnett's multiple comparison; ns

1098 (non-significant). P values are displayed over data. **(D, F, H, K)** Quantification of mean p62

1099 intensity/pixel around LCVs at 0 (D) or 20 (F) or 60 (H) or 180 (K) MPI of vacuoles analyzed in

1100 (C,E,G,J). Image analysis performed on same coverslips at corresponding timepoints. Number

1101 of cells analyzed (n) for each strain at each timepoint is provided in Source Data File. At least 70

1102 vacuoles per replicate were quantified and data were pooled from 3 biological replicates (mean ±

1103 SD; one-way ANOVA with Dunnett's multiple comparison (D, F, H) and Student's two tailed t-

1104 test (K); ns (non-significant). Exact P values are displayed over data. **(I)** A representative

1105 micrograph of p62 association with LCVs at 180 MPI, scale bar 10 μm. **(L)** Kinetics of blockade

1106 against p62 recruitment. All strains described in Supplemental Table S1 (pV: pJB908att-empty).

1107 Data acquired from panels C, E, G and J, and shown as mean ± SEM. All P values are found in

1108 Source Data File. Source data are provided as a Source Data file.

1109

Figure 6. ART activity is sufficient to block p62 recruitment to the replication vacuole.

(A) Quantification of individual LCVs enveloped by p62 at 0 MPI. BMDMs were challenged

with the noted *Legionella* strains. 100 LCVs per replicate were counted in n=3 biological

replicates (mean ± SEM; one-way ANOVA with Dunnett's multiple comparisons; ns (non-

significant). Exact P values are displayed over data. **(B)** Quantitation of mean p62 intensity/pixel

associated with individual LCVs. Images of individual vacuoles were grabbed and pixel

intensities of p62 staining about regions of interest were determined (Methods). At least 198

LCVs were counted from the replicates performed in panel A. Data are shown as means ± SD

(one-way ANOVA with Dunnett's multiple comparison; ns (non-significant). Exact P values are

displayed over data. All P values are found in Source Data File. **(C)** Examples of recruited p62 to

LCVs harboring Δ*sde* expressing SdeC catalytic mutant derivatives. All strains described in

Supplemental Table S1 (pV: pJB908att-empty). Scale bar: 10 μm. Source data are provided as a

Source Data file.

1123

Figure 7. Sde accessory activities drive Rtn4 rearrangements and block autophagic

recognition.

The DUB activity provides fuel for pR-Ub modification of Rtn4, driving rapid ER-associated

rearrangements. **(A)** Bacteria are internalized, Sde family proteins are translocated. **(B)**

Polyubiquitination occurs about the replication vacuole. **(C)** Digestion of polyUb provides Ub

fuel for ART/PDE domain to catalyze pR-Ub conjugation to substrates such as Rtn4. **(D)** Rtn4-

pR-Ub modified protein accumulates about the replication vacuole polyUb is modified by

phosphoribosylation. The pR-modification of the polyUb at R42 residue stabilizes

polyubiquitination about LCVs, simultaneously preventing degradation by host cell-derived

DUBs and blocking recognition by the autophagic machinery.

1134

1135

1136

1137   **Supplemental Table S1.** *Legionella pneumophila* strains used in this study.

1138   **Supplemental Table S2.** *Escherichia coli* strains used in this study

1139   **Supplemental Table S3.** Oligonucleotides used in this study.

1140   **Supplemental Figures S1-S5**

1141

A

	---	NP-	WT	ART-	DUB-
SdeC PreInc
Ub$_{3-7}$ Modification	---	ADPr	pR	---	pR
DUB Rxn (Input/Output)	In O	In O	In O	In O	In O

USP2 Nonspecific

Out-1 K48 preference

CYLD K63 preference

SdeC-DUB K63 preference

K63-Ub$_{3-7}$ K48-Ub$_{3-7}$

D WT
E Δ*sde*

Poly Ub
L.p.
DNA

F Δ*sde*+p*sdeC$_{C118S}$*
G Δ*sde*+p*sdeC$_{E859A}$*

H Δ*sde*+p*sdeC$_{H416A}$*

B

PolyUb Intensity at LCV/Bacterium (AU)

<.0001
.0001
<.0001

pSdeC (WT)   pDUB- (C118S)   pART- (E859A)   pPDE- (H416A)

Δ*sde*+p*sdeC*

C

PolyUb Intensity at LCV/Bacterium (AU)

0.93

20 MPI   60 MPI

Δ*sde*+p*sdeC* PDE- (H416A)

A **B** **C** **D**

L. pneumophila

DUB **ART/NP**

K63-Ub ✔ ✔ Ub—Substrate
Ub Conjugation FUEL

Non-K63-Ub ✗ ✔ Autophagic Block/
Ub Camaflouge

⊂ = Sde proteins

⬤⬤⬤⬤ = K63 Polyubiquitin

⬤ = Monoubiquitin

🔴🔴🔴🔴 = Polyubiquitin (Non-K63)

🟢🟢🟢🟢 = ADPr- or P-ribose-Polyubiquitin